From: Targeting macrophages in hematological malignancies: recent advances and future directions
Type of mAb | Subclass of IgG | Initial time of clinical studies | Phase | Type of tumors | Treatment programs | ClinicalTrials.gov Identifier | |
---|---|---|---|---|---|---|---|
Hu5F9-G4 | mAb | IgG4 | 2014.8 | Phase II | MDS and AML | Combined therapy | NCT02216409 |
Hu5F9-G4 | mAb | IgG4 | 2020.9 | Phase III | Higher-risk MDS | Combined therapy | NCT04313881 |
Hu5F9-G4 | mAb | IgG4 | 2021.11 | Phase II | R/R cHL | Combined therapy | NCT04788043 |
Hu5F9-G4 | mAb | IgG4 | 2021.12 | Phase I | R/R B-Malignancies | Combined therapy | NCT04599634 |
Hu5F9-G4 | mAb | IgG4 | 2022.05 | Phage III | TP53 Mutant AML | Combined therapy | NCT04778397 |
Hu5F9-G4 | mAb | IgG4 | 2022.9 | Phase IB/II | MDS and AML | Combined therapy | NCT05367401 |
TTI-621 | SIRPα fusion protein | IgG1 | 2016.1 | Phase IA/IB | Hematological Malignancies | Monotherapy | NCT02663518 |
TTI-621 | SIRPα fusion protein | IgG1 | 2021.10 | Phase IB | MM | Combined therapy | NCT05139225 |
TTI-622 | SIRPα fusion protein | IgG4 | 2018.5 | Phase IA/IB | Hematological Malignancies | Combined therapy | NCT03530683 |
TTI-622 | SIRPα fusion protein | IgG4 | 2021.1 | Phase IB | R/R MM | Combined therapy | NCT05139225 |
ALX148 | IRPα fusion protein | IgG1 | 2017.2 | Phase I | Lymphoma | Combined therapy | NCT03013218 |
ALX148 | SIRPα fusion protein | IgG1 | 2020.1 | Phase I/II | MDS | Combined therapy | NCT04417517 |
ALX148 | SIRPα fusion protein | IgG1 | 2021.1 | Phase I/II | B-NHL | Combined therapy | NCT05025800 |
ALX148 | SIRPα fusion protein | IgG1 | 2021.5 | Phase I/II | AML | Combined therapy | NCT04755244 |
AK117 | mAb | IgG4 | 2020.4 | Phase I | Lymphoma | Monotherapy | NCT04349969 |
AK117 | mAb | IgG4 | 2021.1 | Phase I | Lymphoma | Monotherapy | NCT04728334 |
AK117 | mAb | IgG4 | 2021.5 | Phase I/II | Higher-risk MDS | Combined therapy | NCT04900350 |
AK117 | mAb | IgG4 | 2021.7 | Phase IB/II | AML | Combined therapy | NCT04980885 |
Gentulizumab | mAb | Un | 2021.4 | Phase I | NHL | Combined therapy | NCT05221385 |
Gentulizumab | mAb | Un | 2021.4 | Phase I | R/R-AML or MDS | Monotherapy | NCT05263271 |
IMM-01 | SIRPα fusion protein | IgG1 | 2019.9 | Phase I | Lymphoma | Monotherapy | ChiCTR1900024904 |
IMM-01 | SIRPα fusion protein | IgG1 | 2022.1 | Phase I/II | MDS and AML | Combined therapy | NCT05140811 |
SRF231 | mAb | IgG4 | 2018.3 | Phase IA/IB | lymphoma/CLL | Combined therapy | NCT03512340 |
SHR1603 | mAb | IgG4 | 2018.1 | Phase I | Lymphoma | Combined therapy | NCT03722186 |
IBI188 | mAb | IgG4 | 2018.12 | Phase I | lymphoma | Combined therapy | NCT03717103 |
IBI188 | mAb | IgG4 | 2020.8 | Phase IB | Newly Diagnosed HR-MDS | Combined therapy | NCT04511975 |
IBI188 | mAb | IgG4 | 2020.9 | Phase IB | AML | Combined therapy | NCT04485052 |
IBI188 | mAb | IgG4 | 2020.9 | Phase IB | Newly Diagnosed HR-MDS | Combined therapy | NCT04485065 |
TJC4 | mAb | IgG4 | 2019.5 | Phase I | lymphoma | Combined therapy | NCT03934814 |
TJC4 | mAb | IgG4 | 2021.6 | Phase IB | MDS and AML | Combined therapy | NCT04912063 |
TJC4 | mAb | IgG4 | 2022.1 | Phase IB | Multiple Myeloma | Combined therapy | NCT04895410 |
ZL-1201 | mAb | IgG4 | 2020.5 | Phase I | Lymphoma | Combined therapy | NCT04257617 |
IMC-002 | mAb | IgG4 | 2020.6 | Phase I | Lymphoma | Combined therapy | NCT04306224 |
AO-176 | mAb | IgG2 | 2020.11 | Phase I/II | Multiple Myeloma | Combined therapy | NCT04445701 |
CC-95251 | mAb | IgG4 | 2019.2 | Phase I | Hematological Cancers | Combined therapy | NCT03783403 |
CC-95251 | mAb | IgG4 | 2022.1 | Phase I | MDS and AML | Combined therapy | NCT05168202 |
CD47 | mAb | Un | 2021.12 | Single-arm | Recurrent AML After Transplantation | Combined therapy | NCT05266274 |